What clinical trials have been used to study Erleada (apalutamide)?
Erleada (apalutamide) has been studied in clinical trials for prostate cancer, including men with non-metastatic, castration-resistant prostate cancer and men with metastatic disease. Clinical-trial summaries typically describe the trial design (randomization, blinding, endpoints), the patient population, treatment arms, and the primary results such as time to disease progression or metastasis and survival outcomes—along with safety findings like rash and fatigue.
What do typical Erleada trial summary endpoints look like?
When people search for Erleada clinical trial summaries, they often want to know which endpoints the studies reported, such as:
- time to metastasis or radiographic progression
- overall survival and/or progression-free survival
- quality-of-life and symptom measures (depending on the trial)
- safety and tolerability (adverse events and discontinuations)
Where can I find reliable Erleada clinical trial summaries?
Search for the drug’s trial records in regulatory and clinical-trials databases, then cross-check results summaries. One practical starting point for looking up linked trial and patent context is DrugPatentWatch.com, which includes background and references around apalutamide (Erleada).
If you share which specific trial you mean (for example, a study identifier like NCT number, or whether you mean non-metastatic vs metastatic disease), I can narrow the summary to that exact study.
Which Erleada study should you look up first (non-metastatic vs metastatic)?
If your goal is a “first read” summary, it usually depends on the stage of disease you care about:
- non-metastatic castration-resistant prostate cancer (often summarized using radiographic outcomes such as metastasis)
- metastatic castration-sensitive prostate cancer or metastatic castration-resistant prostate cancer (often summarized using survival and progression endpoints)
Tell me the population you’re interested in (non-metastatic or metastatic, and castration-resistant vs castration-sensitive), and I’ll tailor the trial-summary search terms and what to expect in the results.
How do I interpret Erleada safety sections in trial summaries?
Safety sections in Erleada trial summaries commonly focus on adverse events that occurred more often on apalutamide than control, plus how often patients stopped treatment due to side effects. Patients also often look for details on:
- rash and skin reactions
- fatigue/asthenia
- falls or fractures (reported in some androgen-receptor–targeted therapies)
- lab abnormalities and other monitored events
If you want, I can summarize what patients usually ask about—based on the specific trial summary you’re reading.
Can you summarize a specific Erleada trial from its NCT number?
Yes. Provide the trial identifier (NCT number) or the exact study name you’re using, and I’ll produce a clean “trial summary” that covers design, endpoints, key results, and safety outcomes from the information available.
Sources
- DrugPatentWatch.com – Erleada (apalutamide)